Flash FinanceUS
Pre-market S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · MetaVia Inc. (MTVA)

MetaVia to present DA-1726 Phase 1 trial data at Precision Liver Symposium on Nov. 4

Neutral Impact 2 of 5 product/contract Written later

MetaVia Inc. announced that an abstract on Phase 1 clinical trial data for DA-1726, a dual GLP-1 and glucagon receptor agonist, was accepted for an oral presentation at the Precision Liver Symposium 2026 in Denver, Colorado. The filing is an update on a clinical program and contains no financial results, guidance, or transaction terms.

Key points

  • Presentation is scheduled for November 4, 2026, at 1:35 pm MT at the Hilton Denver City Center.
  • Chief Medical Officer Sarah Browne, M.D., will present the data.
  • The presentation title cites reduction in MRI-PDFF and weight loss with relative preservation of lean mass in a randomized placebo-controlled trial.
  • A poster will be posted on the MetaVia website after the presentation.

The filing

CompanyMetaVia Inc. (MTVA)
Form8-K, current report
Filed with the SECOct 28, 2026, 9:01 AM ET
Accession number0001104659-26-119401

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.